TEL AVIV, Israel & OSLO, Norway, April 28, 2026
BioLineRx and Hemispherian have announced that the first patient has been successfully dosed in a first-in-human Phase 1/2a clinical trial of GLIX1, a novel investigational therapy targeting glioblastoma (GBM) and other high-grade gliomas. This milestone represents a significant advancement in oncology drug development, particularly for GBM, one of the most aggressive and treatment-resistant cancers with limited therapeutic options. The study is being conducted at leading clinical centers, including NYU Langone Health, and is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GLIX1. The initiation of patient dosing underscores growing momentum in innovative small-molecule therapies aimed at addressing critical unmet needs in neuro-oncology and advancing precision cancer treatment strategies.
First-in-Class Mechanism Targets DNA Damage Pathways
GLIX1 is a first-in-class, oral small molecule designed to activate TET2, a key regulator involved in DNA modification and repair mechanisms. By restoring TET2 activity, the therapy induces selective DNA damage in cancer cells, offering a differentiated approach to targeting tumor survival pathways. This mechanism is particularly relevant in glioblastoma, where TET2 activity is often suppressed, contributing to tumor progression and resistance to conventional therapies.
Preclinical studies have demonstrated potent anti-tumor activity, strong blood-brain barrier penetration, and a favorable safety profile, highlighting its potential as a transformative treatment option. The novel mechanism positions GLIX1 as a promising candidate not only for GBM but also for a broader range of solid tumors reliant on DNA damage repair pathways, reinforcing its significance in next-generation oncology therapeutics.
Phase 1/2a Trial Design Drives Clinical Development
Advertisement
The ongoing Phase 1/2a study follows a dose-escalation design, enrolling up to 30 patients with recurrent or progressive glioblastoma and other high-grade gliomas. The primary objective is to establish the maximum tolerated dose (MTD) and determine a recommended dose based on safety and early efficacy signals. Following this, the Phase 2a expansion will explore additional indications, including newly diagnosed GBM and combination strategies with standard-of-care therapies such as PARP inhibitors.
Initial clinical data from the Phase 1 portion are anticipated in the first half of 2027, providing critical insights into the therapy’s clinical potential. The multi-center trial, conducted across globally recognized institutions, reflects a robust and comprehensive approach to clinical validation, ensuring high-quality data generation and regulatory readiness for future development phases.
Advancing Innovation in Glioblastoma Treatment
Glioblastoma remains one of the most challenging cancers, with minimal therapeutic progress over the past two decades and a persistently poor prognosis. The initiation of GLIX1 clinical development represents a potential paradigm shift in GBM treatment, focusing on targeted molecular mechanisms rather than traditional cytotoxic approaches. From a cGxP perspective, the program demonstrates adherence to Good Clinical Practice (GCP), rigorous trial design, and regulatory compliance, ensuring data integrity and patient safety.
The collaboration between BioLineRx and Hemispherian highlights the growing importance of strategic partnerships in accelerating oncology innovation, combining scientific expertise with clinical execution capabilities. As the trial progresses, GLIX1 could emerge as a next-generation therapeutic platform with the potential to redefine treatment standards in glioblastoma and beyond, offering renewed hope for patients facing this devastating disease.
Source: BioLineRx, Hemispherian press release
